Federal practitioner : for the health care professionals of the VA, DoD, and PHS

Increasing Doses of Semaglutide Under the Skin May Lower Insulin Use in Type 2 Diabetes Patients

Updated

Abstract

Nearly 25% of patients in the US Department of Veterans Affairs health care system have type 2 diabetes mellitus.

  • Semaglutide 2 mg may significantly improve hemoglobin A1c levels compared to semaglutide 1 mg in non-insulin users.
  • The study investigates the impact of increasing semaglutide dosage on total daily insulin requirements.
  • Effects on insulin dosage are not yet reported or concluded.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free